Skip to main content
BEAT logo

BEAT · HeartBeam, Inc. · Documents

Track BEAT — free
$0.28 -0.03 (-8.90%) Play latest call Q3 2026 earnings call transcript
Market Cap
$19.56M
Shares
63.31M
Volume · Nov 20 403.48K Avg daily vol (3M) 7.39M

The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →

Annual report FY2025 Net loss $21.02M 10-K filed Mar 12, 2026 Quarterly report FY2026 Q3 Net loss $3.01M 10-Q filed Nov 12, 2026 Earnings call Q3 2026 earnings call Held Nov 12, 2026
2026
Nov 12
Earnings call
FDA pathway supports accelerated pivotal study plan

HeartBeam aligned with the FDA on a 510k pathway, plans a pivotal study beginning in 2027, reported Q3 2026 operating cash use of $2.6 million, and had pro forma cash of approximately $10.1 million.

4 source passages
the alignment with the FDA on our 510k pathway, which is a super important step. Next in line is our US pivotal study planned, again, for beginning of 2027. Taking a look at the Q3 2026 financials, and we'll focus in on cash flow first. Net cash use and operating activities for $2.6 million in the quarter. So in total, that gives us a pro forma cash balance of approximately $10.1 million. Open the document at this passage
Nov 12
Quarterly report 10-Q FY2026 Q3, ended Sep 30
FDA grants heart attack assessment breakthrough designation

HeartBeam, Inc. received FDA Breakthrough Device Designation for heart attack assessment on October 5, 2026. ALIGN-ACS showed 81.8% specificity versus 71.4% for 12-lead ECG; Nasdaq compliance is due by December 28, 2026, and cash is insufficient for twelve months.

Net loss $3.01M Diluted EPS -$0.05
Read from the MD&A section
5 source passages
On October 5, 2026, the Company received FDA Breakthrough Device Designation for Heart Attack Assessment. Positive results from the ALIGN-ACS pilot study were presented by Graham Nichol, MD, MPH, FRCP(C), of the University of Washington, at the Transcatheter Cardiovascular Therapeutics (TCT) 2026 conference. HeartBeam’s 3D ECG technology was shown to be as accurate as the standard 12-Lead ECG. The device demonstrated higher specificity than standard 12-lead ECG (81.8% vs. 71.4%), with comparable sensitivity. On June 30, 2026, the Company received a deficiency letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC notifying the Company that the closing bid price of its common stock had fallen below the $1.00 per share minimum bid price requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has a compliance period of 180 calendar days, or until December 28, 2026, to regain compliance. Based on our current business plan assumptions and expected cash burn rate, the Company believes that the existing cash is insufficient to fund operations for the next twelve months following the issuance of these financial statements. Open the document at this passage
Mar 12
Annual report 10-K FY2025, ended Dec 31
Annual report for FY2025 AI summary on its way
Net loss $21.02M Diluted EPS -$0.62
2025
2024
Showing 1–50 of 108 documents
Key facts CIK 1779372 13F (30d) 39 filings 36 filers Visit website Investor relations